Knowledge at the heart of leadership
Welcome to Liftstream - Life Sciences Executive Search and Leadership Advisory

Prosensa announces senior management and board appointments

Authored by Karl Simpson

Prosensa HoldingsN.V, the drug development company focused on advancing therapies for duchenne muscular dystrophy announced the appointment of Willem W. van Weperen to the new position of chief commercial officer and the addition of Dr. Annalisa Jenkins to its Supervisory Board.

With more than two decades of experience at Genzyme and GSK and his recent leadership of Dutch to-BBB as CEO, Mr. van Weperen brings significant business operational and commercial expertise to Prosensa.

Dr. Annalisa Jenkins joins Prosensa’s Supervisory Board with more than 25 years of experience in the healthcare sector. In her most recent role as Head of Global Research and Development and Executive Vice President at Merck Serono, which she has held since October 2013, she was responsible for building global development, research and medical capabilities, spanning research, development, global regulatory and clinical development in addition to medical affairs and patient access.

“We are delighted to welcome Annalisa to Prosensa’s Supervisory Board. Her extensive experience in research and clinical development and medical affairs for Merck Serono and Bristol Myers Squibb, which are amongst the top pharma companies in the world, will bring valuable insights to us as we take the company to the next level,” said David Mott, Chairman of the Supervisory Board at Prosensa.

The appointment of Dr. Annalisa Jenkins will be subject to shareholders’ approval at the next shareholders’ meeting, scheduled for August 20, 2014.

Posted in Executive Appointments, Orphan Drugs and Rare Diseases, Recruitment Market | Tagged , , , , , , , , , , , , | Leave a comment




Contact Us

   Liftstream Ltd.
67 Grosvenor Street
London
W1K 3JN

   Tel: ​+44 (0)20 3178 5864
   info@liftstream.com

Register your CV

Apply for sector specific vacancies or request a confidential discussion



Registered in England No: 5009233
VAT: 843679292

Follow Us





Sitemap